The effect of sequential antiresorptive therapy after denosumab discontinuation on fracture risk: a systematic review and meta-analysis
Discontinuation of denosumab (DMAb) causes a rapid rebound in bone turnover and increases the risk of multiple vertebral fractures. However, the optimal sequential antiresorptive strategy and its specific timing remain uncertain. We systematically searched PubMed, Embase, Web of Science, and Cochrane Libra...